Infectious Diseases

The evolving landscape of infectious diseases

Global challenges & therapeutic limitations

Infectious diseases caused by viruses, bacteria, and other pathogens continue to account for significant morbidity and mortality worldwide. Viral outbreaks, antimicrobial-resistant bacteria, and chronic infections such as human immunodeficiency virus 1 (HIV-1) or hepatitis B virus (HBV) remain major clinical challenges.

Traditional therapies often rely on small-molecule antivirals or antibiotics that target specific pathogen proteins. However, high mutation rates in viruses and the rapid emergence of antimicrobial resistance frequently reduce long-term efficacy. Additionally, broad-spectrum treatments can disrupt normal microbiota and lead to unintended side effects. These challenges highlight the need for innovative strategies that are rapidly adaptable, pathogen-specific, and capable of modulating host immune responses.

From pathogen suppression to molecular targeting

Conventional treatments primarily aim to inhibit pathogen replication or kill infectious agents directly. In contrast, nucleic acid–based approaches enable precise molecular intervention — targeting viral genomes, silencing resistance genes, expressing protective antigens, or enhancing host immunity.

This shift toward programmable molecular targeting allows rapid redesign in response to new variants or emerging pathogens. By directly modulating gene expression in pathogens or host cells, next-generation therapeutics offer a powerful framework for precision infectious disease management.

How do nanoparticle technologies enable infectious disease therapeutics?

Overcoming in vivo delivery barriers

Nucleic acids are inherently unstable in biological environments and face enzymatic degradation, rapid clearance, and poor cellular uptake. Efficient delivery to the appropriate immune cells or infected tissues is essential for therapeutic efficacy.

Nanoparticle platforms — including lipid-based and polymer-based systems — protect nucleic acids from degradation, enhance cellular internalization, and enable cytosolic release. Their physicochemical properties can be engineered to optimize biodistribution and immune activation.

While viral vectors have also been explored for infectious disease applications, non-viral nanoparticle systems offer improved safety profiles, manufacturing scalability, and flexibility for rapid reformulation.

Where are nanoparticle platforms applied in infectious diseases?

Key therapeutic applications

• Prophylactic vaccination – Nanoparticle–based mRNA vaccines enable rapid antigen expression and robust immune responses against pathogens.
• Therapeutic vaccines – Nanoparticles can deliver nucleic acids that enhance immune recognition of chronic infections such as HIV or hepatitis B.
• Direct antiviral gene silencing – siRNA and ASO delivery platforms can selectively suppress viral RNA replication within infected cells.
• CRISPR-based antiviral strategies – Nanocarriers enable delivery of gene editing components designed to target and degrade viral genomes.
• Antimicrobial resistance targeting – Nucleic acid therapeutics can silence resistance genes in bacteria, restoring antibiotic sensitivity.
• Immune modulation – Nanoparticles can deliver cytokine-encoding mRNA or immunostimulatory RNA to enhance host defense mechanisms.